The DOI matches its OpenAlex record; 14 of the 14 references it cites were found in a registry or an index.
Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma
Open accessAbstract
PURPOSE: A strain of Salmonella typhimurium (VNP20009), attenuated by chromosomal deletion of the purI and msbB genes, was found to target to tumor and inhibit tumor growth in mice. These findings led to the present phase I study of the intravenous infusion of VNP20009 to patients with metastatic cancer. PATIENTS AND METHODS: In cohorts consisting of three to six patients, 24 patients with metastatic melanoma and one patient with metastatic renal cell carcinoma received 30-minute intravenous bolus infusions containing 10(6) to 10(9) cfu/m(2) of VNP20009. Patients were evaluated for dose-related toxicities, selective replication within tumors, and antitumor effects. RESULTS: The maximum-tolerated dose was 3 x 10(8) cfu/m(2). Dose-limiting toxicity was observed in patients receiving 1 x 10(9) cfu/m(2), which included thrombocytopenia, anemia, persistent bacteremia, hyperbilirubinemia, diarrhea, vomiting, nausea, elevated alkaline phosphatase, and hypophosphatemia. VNP20009 induced a dose-related increase in the circulation of proinflammatory cytokines, such as interleukin (IL)-1beta, tumor necrosis factor alpha, IL-6, and IL-12. Focal tumor colonization was observed in two patients receiving 1 x 10(9) cfu/m(2) and in one patient receiving 3 x 10(8) cfu/m(2). None of the patients experienced objective tumor regression, including those patients with colonized tumors. CONCLUSION: The VNP20009 strain of Salmonella typhimurium can be safely administered to patients, and at the highest tolerated dose, some tumor colonization was observed. No antitumor effects were seen, and additional studies are required to reduce dose-related toxicity and improve tumor localization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dinarello, C. A. (2000) · Chest · doi:10.1378/chest.118.2.503 · Cited by 2,045
Tumor-targeted Salmonella as a novel anticancer vector.
Pawelek, J. M., Low, K. B., & Bermudes, D. G. (1997) · PubMed · Cited by 527
Proinflammatory and Anti-inflammatory Cytokines as Mediators in the Pathogenesis of Septic Shock
Dinarello, C. A. (1997) · Chest · doi:10.1378/chest.112.6_supplement.321s · Cited by 508
Low, K. B., Ittensohn, M., Le, T., Platt, J., Sodi, S., Amoss, M., Ash, O., Carmichael, E., Chakraborty, A., Fischer, J., et al. (1999) · Nature Biotechnology · doi:10.1038/5205 · Cited by 476
Regulation of the Proinflammatory Effects of Fas Ligand (CD95L)
Chen, J.-J., Sun, Y., & Nabel, G. J. (1998) · Science · doi:10.1126/science.282.5394.1714 · Cited by 383
Clairmont, C., Lee, K. C., Pike, J., Ittensohn, M., Low, K. B., Pawelek, J., Bermudes, D., Brecher, S. M., Margitich, D., Turnier, J., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315497 · Cited by 355
Eaves-Pyles, T., Murthy, K., Liaudet, L., Virág, L., Ross, G., Soriano, F. G., Szabó, C., & Salzman, A. L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.2.1248 · Cited by 270
Salmonellosis — A Review of Some Unusual Aspects
Black, P. H., Kunz, L. J., & Swartz, M. N. (1960) · New England Journal of Medicine · doi:10.1056/nejm196004212621606 · Cited by 255
Freudenberg, M. A., & Galanos, C. (1988) · Infection and Immunity · doi:10.1128/iai.56.5.1352-1357.1988 · Cited by 229
A lethal role for lipid A in Salmonella infections
Khan, S. A., Everest, P., Servos, S., Foxwell, N., Zähringer, U., Brade, H., Rietschel, E. T., Dougan, G., Charles, I. G., & Maskell, D. J. (1998) · Molecular Microbiology · doi:10.1046/j.1365-2958.1998.00952.x · Cited by 212
Salmonella-Induced Caspase-2 Activation in Macrophages
Jesenberger, V., Procyk, K. J., Yuan, J., Reipert, S., & Baccarini, M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1035 · Cited by 178
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer
Otto, F., Schmid, P., Mackensen, A., Wehr, U., Seiz, A., Braun, M., Galanos, C., Mertelsmann, R., & Engelhardt, R. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00186-4 · Cited by 97
Saltzman, D. A., Katsanis, E., Heise, C. P., Hasz, D. E., Vigdorovich, V. I., Kelly, S. M., Curtiss, R., Leonard, A. S., & Anderson, P. M. (1997) · Journal of Pediatric Surgery · doi:10.1016/s0022-3468(97)90198-6 · Cited by 61
Infection of a Secondary Carcinoma by Salmonella montevideo
Graham, F., & Coleman, P. N. (1952) · BMJ · doi:10.1136/bmj.1.4768.1116 · Cited by 29
Research works printed but not linked: 6
- 10.1056/NEJM195412092512406 · doi:10.1056/nejm195412092512406
- Simmers TA, Mijnhout GS, Van Meyel JJ : Salmonellosis: An unusual complication of hepatocellular carcinoma. Scand J Gastroenterol 32: 1180,1997-1182, · doi:10.3109/00365529709003000
- 10.1016/S0163-4453(87)91476-9 · doi:10.1016/s0163-4453(87)91476-9
- 10.1056/NEJM196005052621806 · doi:10.1056/nejm196005052621806
- 10.1093/clinids/8.1.31 · doi:10.1093/clinids/8.1.31
- Carrier MJ, Chatfield SN, Dougan G: Expression of human IL-1 beta in : A model system for the delivery of recombinant therapeutic proteins in vivo. J Immunol 148: 1176,1992-1181,Salmonella typhimurium · doi:10.4049/jimmunol.148.4.1176
Cited by
Microbiota in health and diseases
Hou, K., Wu, Z.-X., Chen, X.-Y., Wang, J.-Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00974-4 · Cited by 3,171
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Bio-inspired, bioengineered and biomimetic drug delivery carriers
Yoo, J.-W., Irvine, D. J., Discher, D. E., & Mitragotri, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3499 · Cited by 1,236
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Metadata
- Authors
- Toso, J. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-01-01
- Volume
- 20
- Issue
- 1
- Pages
- 142-152
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2150565980
- Cited by
- 614
- References
- 14
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.